Nazila Assasi

Summary

Affiliation: McMaster University
Country: Canada

Publications

  1. ncbi Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
    Feng Xie
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    Cost Eff Resour Alloc 7:20. 2009
  2. ncbi Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
    Gord Blackhouse
    PATH Research Institute, McMaster University, Hamilton, Ontario, Canada
    Cost Eff Resour Alloc 8:14. 2010
  3. ncbi Patient outcomes after anti TNF-alpha drugs for Crohn's disease
    Nazila Assasi
    Programs for Assessment of Technology in Health Research Institute, St Joseph s Healthcare, Hamilton, 25 Main Street West, Suite 2000 ON, Canada
    Expert Rev Pharmacoecon Outcomes Res 10:163-75. 2010
  4. ncbi Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura
    Feng Xie
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    Clin Ther 31:1082-91; discussion 1066-8. 2009

Detail Information

Publications4

  1. ncbi Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
    Feng Xie
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    Cost Eff Resour Alloc 7:20. 2009
    ..Future research could be aimed at the long-term clinical benefits of these drugs, especially adalimumab for patients intolerant or unresponsive to infliximab treatment...
  2. ncbi Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
    Gord Blackhouse
    PATH Research Institute, McMaster University, Hamilton, Ontario, Canada
    Cost Eff Resour Alloc 8:14. 2010
    ..The objective of the paper is to evaluate, from a Canadian perspective, the cost-effectiveness of IVIG compared to corticosteroid treatment of CIDP...
  3. ncbi Patient outcomes after anti TNF-alpha drugs for Crohn's disease
    Nazila Assasi
    Programs for Assessment of Technology in Health Research Institute, St Joseph s Healthcare, Hamilton, 25 Main Street West, Suite 2000 ON, Canada
    Expert Rev Pharmacoecon Outcomes Res 10:163-75. 2010
    ..The review further considers the evidence for the harms and benefits associated with switching from one anti-TNF-alpha agent to another and strategies to optimize the timing of therapy...
  4. ncbi Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura
    Feng Xie
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    Clin Ther 31:1082-91; discussion 1066-8. 2009
    ..The aim of this work was to estimate the cost-effectiveness of intravenous immunoglobulin (IVIg) compared with oral prednisone as a treatment for Canadian adults with persistent chronic immune thrombocytopenic purpura (ITP)...